Concourse Financial Group Securities, Inc. Xilio Therapeutics, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $0
- Q1 2025
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
100.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding XLO
# of Institutions
34Shares Held
11.1MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA4.57MShares$3.11 Million1.1% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$980,18116.6% of portfolio
-
Morgan Stanley New York, NY1.16MShares$785,9690.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.14MShares$772,2860.0% of portfolio
-
Aju Ib Investment Co., Ltd. Seoul, M5668KShares$454,0640.57% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $18.7M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...